Recruiting
Neoplasm
RecruitingPhase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations
Registered drugNo placebo
Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations
Registered drugNo placebo
- Disease:Neoplasm
- Substances:FulvestrantLY3484356
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Fulvestrant
- Sponsor:Terremoto Biosciences Inc.




